As Novo Nordisk continues to dominate the pharmaceutical industry with its diabetes and obesity drugs, Ozempic and Wegovy, the company faces mounting scrutiny over its […]
As Novo Nordisk continues to dominate the pharmaceutical industry with its diabetes and obesity drugs, Ozempic and Wegovy, the company faces mounting scrutiny over its […]